Repaglinide Tablet
Description
REPAROOT-1
Repaglinide 1 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Repaglinide IP — 1 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
REPAROOT-1 contains Repaglinide 1 mg, a rapid-acting insulin secretagogue formulated for the effective management of Type 2 Diabetes Mellitus. Repaglinide stimulates pancreatic beta cells to release insulin in response to meals, helping control postprandial blood glucose levels and improve overall glycemic control.
Repaglinide is particularly effective in reducing postprandial hyperglycemia, an important contributor to poor glycemic control and long-term diabetic complications. Due to its rapid onset and short duration of action, Repaglinide offers flexible meal-time dosing and allows individualized treatment according to the patient’s eating pattern.
REPAROOT-1 is especially beneficial for patients initiating Repaglinide therapy, individuals with mild to moderate postprandial hyperglycemia, elderly patients, and those requiring individualized dose titration or combination therapy with other antidiabetic agents.
Technical Knowledge of Repaglinide
Repaglinide belongs to the meglitinide class of oral antidiabetic agents. It stimulates insulin secretion by binding to ATP-sensitive potassium channels on pancreatic beta cells, causing membrane depolarization, calcium influx, and glucose-dependent insulin release.
Its rapid absorption and short elimination half-life provide effective postprandial glucose control while reducing prolonged insulin exposure between meals. This pharmacokinetic profile offers greater flexibility in meal-time dosing and individualized diabetes management.
Mechanism of Action
Repaglinide stimulates pancreatic beta cells, closes ATP-sensitive potassium channels, increases calcium influx, promotes rapid insulin secretion, reduces postprandial blood glucose excursions, and improves overall glycemic control.
Key Benefits
Effective control of postprandial blood glucose
Rapid onset of antidiabetic action
Flexible meal-time dosing
Improves overall glycemic control
Supports individualized diabetes management
Can be used alone or in combination therapy
Helps reduce glucose fluctuations after meals
Suitable for initiation and long-term diabetes management under medical supervision
Clinical Applications
REPAROOT-1 is commonly prescribed for Type 2 Diabetes Mellitus, postprandial hyperglycemia, initiation of oral antidiabetic therapy, inadequate glycemic control with diet and exercise, combination therapy with metformin, combination therapy with other oral antidiabetic agents, and individualized meal-time diabetes management.
Facts About Repaglinide
Repaglinide is a rapid-acting insulin secretagogue specifically designed for meal-time glucose control. It has a faster onset and shorter duration of action than sulfonylureas, making it particularly useful for controlling postprandial hyperglycemia and for patients with variable meal schedules. The 1 mg strength is especially useful for initiating therapy and for patients requiring gradual dose adjustment.
Key Facts
Rapid-acting meglitinide antidiabetic agent
Repaglinide 1 mg for postprandial glucose control
Stimulates glucose-dependent insulin secretion
Provides flexible meal-time dosing
Suitable for therapy initiation and dose titration
Evidence-based oral antidiabetic therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
REPAROOT-1 is an excellent product for PCD Pharma Franchise, Diabetology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of Type 2 diabetes, obesity, metabolic syndrome, and lifestyle-related metabolic disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose REPAROOT-1 for PCD Pharma Franchise?
High prescription potential
Strong physician and diabetologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Repaglinide 1 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
REPAROOT-1 from DIABGLYM combines effective postprandial glucose control, flexible meal-time dosing, evidence-based diabetes therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, diabetologists, endocrinologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Repaglinide formulation.
